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Alterations in glomerular RNA in diabetic rats: Roles of insulin anti
glucagon. Incorporation in vivo of labeled orotate into RNA and total
nucleotides was measured in isolated glomeruli and whole renal cortex.
In 2-day diabetic animals, glomerular RNA was increased, and there
was greater incorporation of orotate into total nucleotides and RNA as
compared with controls. Insulin reversed the exaggerated incorporation
at infusion rates that corrected hyperglucagonemia without reducing
plasma glucose and with only minimal changes in insulin concentra-
tions. The addition of glucagon to insulin infusions reproduced the
increased incorporation observed in untreated diabetics. Similar
changes occurred in renal cortex, where differences in orotate incorpo-
ration into nucleotide precursors seemed to be the main cause for
alterations in RNA labeling. Isotope incorporation in glomeruli correlat-
ed positively with plasma glucagon, but not with insulin or glucose
concentrations. Although in 7-month diabetic animals orotate incorpo.
ration into RNA was less than in controls, probably as a consequence o1
renal disease, 24-hour insulin infusion decreased it further. Our results
confirm that in the diabetic kidney, abnormal uracil nucleotide metabo-
lism and increased cellular content of RNA are demonstrable in
glomeruli as in the renal cortex. These changes appear to be related
directly to hyperglucagonemia.
Modifications du RNA glomérulaire chez les rats diabetiques: Roles de
l'insuline et du glucagon. L'incorporation in vivo d'orotate marqué dans
le RNA et les nucléotides totaux a étb mesurée dans des glomérules
isolés et l'ensemble du cortex renal. Chez des animaux diabetiques de 2
jours Ic RNA glomerulaire était augmenté et il y avait une plus grande
incorporation de l'orotate dans les nucléotides totaux par comparaisort
aux contrOles. L'insuline a renversé cette augmentation de l'incorpora--
tion a des debits de perfusion qui corrigent l'hyperglucagonémie sans
diminuer Ic glucose plasmatique et avec seulement des modifications
minimes de Ia concentration d'insuline. L'addition de glucagon a La
perfusion d'insuline reproduit l'augmentation d'incorporation observée
chez les diabétiques traités. Des modifications semblables sont obser.
vées dans Ic cortex renal oh des differences de l'incorporation d'orotate
dans les precurseurs des nucléotides semblent être Ia cause principale
des modifications du marquage du RNA. L'incorporation d'isotopes
dans les glomCrules est positivement corrClée avec le glucagon plasma.
tique mais pas avec les concentrations d'insuline et de glucose. Bien
que chez les animaux diabetiques de 7 mois I'incorporation d'orotate
dans Ic RNA soit moindre que chez les contrôles, probablement en
fonction de l'atteinte rdnale, La perfusion d'insuline sur 24 heures La
diminue encore. Nos résultats confirment que dans le cortex de rein
diabetique un metabolisme anormal des nucléotides et une augmenta-
tion des contenus cellulaires en RNA peuvent étre mis en evidence. Ces
modifications paraissent être liées directement a l'hyperglucagonemie.
[1, 2]. The increase in GFR is accompanied by morphologic
changes of glomerular hypertrophy [3]. The volume of the
capillary tuft and the diameter of the capillary lumina are
significantly increased, although the number of glomerular cells
remains constant. Direct measurements of isolated glomeruli
demonstrate increased size and weight [4, 5]. Anatomic and
functional evidence of renal hypertrophy exists also in experi-
mental diabetes [6, 7]. In addition, cortical RNA content, RNA
synthesis rate, and the formation of uracil nucleotides from
orotate are all increased 2 days after induction of diabetes with
streptozotocin in the rat [8].
These metabolic abnormalities resemble some of those ob-
served at the initiation of compensatory renal growth [8, 9].
Shortly after unilateral nephrectomy, there is enhanced cortical
synthesis of uracil nucleotides and of RNA and a rapid increase
in RNA content [10]. These biochemical changes and the
compensatory growth of the remaining kidney are augmented
after unilateral nephrectomy in diabetic animals [8, 9].
The accentuated renal growth in diabetes may be relevant to
the pathogenesis of diabetic glomerular disease. Unilateral
nephrectomy accelerates the development of diabetic glomeru-
lar lesions in the remaining kidney of rats injected with strepto-
zotocin [II]. In man, also, compensatory renal growth may
accelerate the appearance of diabetic lesions. In diabetic recipi-
ents of transplanted kidneys, characteristic glonierular lesions
have been found to develop in the organ undergoing compensa-
tory growth earlier than would be expected from the natural
course of the renal complications of the disease [12—141. Altered
glomerular microcirculatory dynamics during compensatory
growth have been proposed as enhancing the severity of
diabetic glomerular lesions [11]. Alternatively, the additive
effects of compensatory growth and diabetes on specific bio-
chemical changes common to both conditions offer a metabolic
basis for the rapid development of glomerular disease.
It is not known if the metabolic alterations observed in the
whole diabetic renal cortex occur also in the glomerulus, where
the abnormalities induced by long-term diabetes have their
Insulin-dependent diabetes in man is characteristically asso-
ciated with an increased GFR and renal size that are evident at
the onset of the disease and that persist for as long as 18 years
491
Received for publication July 17, 1980
and in revised form February 4, 1981
0085-2538/81/0020-0491 $01.80
© 1981 by the International Society of Nephrology
492 Cortes et a!
greatest clinical implications. In addition, the factors mediating
the biochemical changes in the kidney in the early stages of
experimental diabetes are not defined. Strict control of diabetes
from its onset corrects the increased renal size and GFR in man
[15] and reverses the metabolic changes in the renal cortex of
the diabetic rat [7, 8]. But, the relative importance of individual
hormonal abnormalities or of hyperglycemia as mediators of the
renal changes remains unknown.
This study represents the first investigation of the metabolism
of RNA in diabetic glomeruli. Glomerular RNA content and
incorporation of exogenous precursors into RNA have been
studied in vivo in short- and long-term diabetic rats, and the
glomerular metabolic changes compared with those occurring
simultaneously in the whole renal cortex of short-term diabetic
animals. The roles of insulin, glucagon, and glucose have been
evaluated separately as factors influencing glomerular metabo-
lism in diabetes.
Methods
Charles River CD-F male rats weighing 160 to 200 g were
used. Cannulae were inserted into the left femoral vein [8, 10],
and animals were left to recover from surgery for 14 days before
any experiments were carried out. After this period, they had
resumed a normal rate of weight increase. Animals had free
access to food and water throughout the duration of the studies
to avoid adverse effects of dietary restrictions on renal growth
[16]. Diabetes was induced by the i.v. injection of streptozoto-
cm (50 mg/kg; U-9889, a gift from the Upjohn Co., Kalamazoo,
MI) dissolved in 0.15 M sodium chloride acidified to a pH of 4.0
with 0.1 M citrate buffer [17]. Controls were age-matched and
injected with the same volume of acidified 0.15 M sodium
chloride.
The following experimental groups were studied. Group I. To
compare purine and pyrimidine metabolism, we infused control
and 48-hour diabetic animals with [5-3H]-orotic acid or [2-H]-
adenine. Treated diabetic animals received a continuous infu-
sion of insulin for the last 38 hours of the experiment. Group2.
To study the effects of glucagon, we treated separate groups of
48-hour diabetic animals with a continuous infusion of insulin or
insulin plus glucagon for the last 38 hours of the experiment and
infused them with [5-3FT]-orotic acid. Group 3. To study the
effects of long-term diabetes, we infused control and 7-month
diabetic animals with [5-3HJ-orotic acid, Diabetic animals treat-
ed with insulin received a continuous infusion for the last 24
hours of the experiment. For the measurement of glomerular
RNA content in an adequate number of glomerular prepara-
tions, noninfused normal and 48-hour diabetic animals were
used.
In experimental groups 1 and 3, control and diabetic animals
received a continuous i,v, infusion of 0.15 M sodium chloride.
To this solution, 173.6 to 463 mU/mI insulin (Regular Iletin®, E.
Lilly Co., Indianapolis, Indiana) was added in the treated
diabetic groups. In group 2, control and diabetic animals were
infused with 0.07 M sodium chloride solution containing 1%
bovine serum albumin (fraction V, Sigma Chemical Co., St.
Louis, Missouri), and 0.05 M sodium phosphate buffer (pH,
7.40). To this, insulin (115.7 to 254.6 mU/mi) with or without
glucagon (200-400 ng/ml; E. Lilly Co.) were added in the treated
diabetic animals. Infusates containing insulin in albumin solu-
tion delivered greater amounts of the hormone because losses
due to surface adsorption were minimized. All infusions were
given to unanesthetized animals at a rate of 3 p.1/mm.
Sodium orotate or adenine hydrochloride and their corre-
sponding radiolabeled compounds were added to the infusates
during the last 2 hours of the infusion period. Each animal
received 60 ii.Ci of [5-3H]-orotic acid (specific activity, 20 Ci/
mmoie) or 89.4 p.Ci of [5-3H]-adenine (specific activity, 16.6 Ci!
mmole) and a total of 0.1 p.moles of the appropriate precursor.
At the end of the infusion period, both kidneys were removed
and rapidly immersed in 0.15 M sodium chloride at 2° C. A
portion of renal cortex from each animal in group 3 was fixed in
buffered formaldehyde for light-microscopic examination of
PAS-stained sections.
In some animals in group 2, the left kidneys were exteriorized
through a lumbar incision. Before ligation of the renal pedicle
and removal of the kidney for glomerular isolation, a sample of
cortex was obtained with immediate freezing in liquid nitrogen
as previously described [10]. Contaminating blood and any
medullary portion included in the samples were scraped from
the cortex under liquid nitrogen. Tissue samples weighing 200
to 300 mg were pulverized in a pre-cooled stainless-steel mortar
and homogenized in 0.2 M perchloric acid at 2° C. The acid-
soluble fraction was used for the quantitative analysis of uridine
triphosphate (UTP) by ion-exchange high-pressure liquid chro-
matography [18]. As an internal standard, 0.25 p.Ci of [2-14CJ-
UTP was added to each sample for assessment of UTP recov-
ery. RNA and DNA were extracted from the acid-insoluble
fraction by alkaline hydrolysis in 0.3 M potassium hydroxide
and by acid hydrolysis in I M perchloric acid, respectively [19].
At the termination of each experiment, blood samples were
obtained by cardiac puncture using heparinized plastic sy-
ringes. Plasma was immediately separated at 2° C and portions
taken for the measurement of glucose, immunoreactive insulin
(IRI), and urea nitrogen. A sample of blood was mixed with a
kallikrein-trypsin inhibitor (500 U/mi, Trasylol, Farbenfabri-
ken Bayer, New York, New York) for plasma immunoreactive
glucagon (IRG) measurements.
Renal cortical tissue from animals in each experimental group
was dissected from medullae and pooled. The tissue was
minced, forced through a 120-mesh sieve, and the glomeruli
were separated by graded sieving at 2°C [18, 20]. Storage of the
samples for up to 3 hours at this temperature does not affect the
recovery of glomerular RNA and DNA [18]. The purity and
glomerular concentration of each isolate was assessed by light-
microscopic examination of the final suspensions. A purity of
95% or greater was obtained. Two samples, each containing
about 64 x l0 glomeruli, were obtained from each glomerular
suspension and stored at —40° C until processed. Glomerular
yield per renal cortex was approximately 10.6 x l0.
Glomerular samples, suspended in 3 ml of 0.15 M sodium
chloride, were homogenized at 2° C in all-glass homogenizers.
Free nucleotides were separated from nucleic acids and pro-
teins by precipitation of the latter in 0.34 M perchloric acid at 2°
C after which RNA and DNA were extracted by methods
identical to those described above for the renal cortical sam-
ples. RNA and DNA were quantified in triplicate by their
pentose content as determined by the orcinol and diphenyl-
amine reactions, respectively [21, 22]. With these methods, 0.6
p.g of ribose is equivalent to I p.g of yeast RNA (type I, Sigma),
and 0.13 p.g of deoxyribose is equivalent to 1 p.g of calf thymus
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DNA (type I, Sigma). Total protein was measured by the
method of Lowry et al [23] with crystalline bovine serun
albumin as standard (Sigma). Plasma glucose and urea nitrogen
were quantified by the glucose oxidase method using the
Beckman glucose analyzer-Il and with the Dupont automated
clinical analyzer, respectively.
Plasma immunoreactive insulin and glucagon were measured
by double-antibody radioimmunoassay methods [24, 251 with
rat insulin and porcine glucagon as standards (Novo Research
Institute, Bagsvaerd, Denmark).
Total free nucleotides in acid-soluble samples, collected
chromatographic fractions, and extracts of RNA were analyzed
for radioactivity in a liquid-scintillation counter (LS-350, Beck-
man Instruments, Fullerton, California). Where required, the
perchloric acid in the samples was neutralized with I M Tris
base buffer before counting. A xylene-based commercial scintil-
lator for aqueous samples was used (ACS. Amersham, Arling-
ton Heights, Illinois). Efficiency of counting was from 35 to
38%.
RNA and DNA values are expressed as their pentose equiva-
lents. Incorporation values are presented as fractions of the
disintegrations per minute (dpm) infused per 200 g of body
weight to correct for the small changes in mean weight present
between animals in different experimental groups in the studies
on short-term diabetics. In experiments on long-term diabetic
animals, the amount of labeled precursor to he infused was
based on body weight because there were large differences
between diabetic and control animals (control) 332 12 g (N =
7), diabetic 160 6 g (N = 15). The amount of UTP incorporat-
ed into RNA was calculated as dpm incorporated into RNA per
one half of the specific activity of UTP obtained at the end of
the infusion with labeled orotate. The mean UTP specific
activity for the entire labeling period is equivalent to one-half
the final value because incorporation of orotate into UTP
increases linearly during a continuous infusion [81. Final UTP
recovery for extraction and quantitation methods in the renal
cortical samples was between 66% and 82%. Results were
expressed per unit of DNA, because this is the reference of
choice to evaluate compositional tissue changes during growth
[28] and is the only renal component that remains constant in
the total organ during the early stages of both compensatory
and diabetic hypertrophy [7, 16]. Selection of glomerular DNA
as a reference is equivalent to the expression of metabolic
changes per cell because of the uniploidy of glomerular cells.
All results are presented as means SEM with number of
observations in parenthesis. The statistical significance of the
differences was determined by Student's t test for nonpaired
variables and by linear regression analysis. The significance of
the linearity of the regressions was tested by means of analysis
of variance.
Results
Incorporation of radiolaheled precursors into glomerular
RNA and total nucleotides in ear/v diabetes: Ejfrcts of insulin
(group 1). Forty-eight hours after streptozotocin injection.
plasma glucose and immunoreactive glucagon (IRG) were in-
creased by 127% and 32%, respectively, and plasma immunore-
active insulin (IRI) was reduced to less than 10% of control
values (Fig. 1). The fraction of labeled orotate incorporated at
the end of the labeling period into glomerular RNA and total
Control 0 2.6 5.2 6.95
Rate of insulin infusion, mu/kg/rn/n
Fig. 1. Plasma glucose, immunoreactive insulin and immunoreactive
glucagon concentrations in 48-hour diabetic animals: Effect of insulin
infusion. Values are means SEM in groups of 8 to 12 diabetic (closed
circles) or control (open circles) animals.
nucleotides in diabetics was about twofold the amount incorpo-
rated in controls (Figs. 2 and 3). Labeled adenine was incorpo-
rated to a greater extent than orotate into both glomerular RNA
and total nucleotides, but no differences were found between
diabetics and controls (Figs. 2 and 3).
The continuous administration of insulin for a period of 38
hours to diabetic animals at increasing rates resulted in progres-
sive reduction of the exaggerated incorporation of orotate into
glomerular RNA (Fig. 2). This effect was evident at infusion
rates (2.6 and 5.2 mU/kg/mm) insufficient to correct hyperglyce-
mia or hypoinsulinernia, although the rates were sufficient to
decrease IRG concentrations to values similar to or lower than
those in controls (Figs. 1, 2). For example, at the lowest
infusion rate tested (2.6 mU/kg/mm), there was a small increase
in plasma IRI (from 9 to 19% of control values) and no decrease
in plasma glucose concentrations, but IRG concentrations were
reduced (P < 0.005) from those found in diabetics to control
levels (Fig. 1). The excessive incorporation of orotate was
totally prevented by a higher infusion rate of insulin (5.2 mL/kg/
mm), which resulted in plasma concentrations of glucose and
insulin that were between control and diabetic values (Fig. 1).
Insulin administration corrected the increased incorporation
of orotate into glomerular RNA to a greater degree than it did
into total nucleotides. Only at the highest infusion rates used
(6.95 mU/kg/mm) was incorporation into total nucleotides re-
duced to control values (Fig. 3).
Relative effects of glucose, insulin, and glucagon on the
incorporation of labeled orotate into glomerular RNA in short-
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Control 0 2.6 5.2 6.95
Rate of insulin infusion, mu/kg/mitt
Fig. 2. Incorporation of radiolabeled orotate and adenine into glomeru-
lar RNA in 48-hour diabetic animals.' Effect of insulin infusion. Obser-
vations were carried out in the same groups of animals as in Fig. 1. In
every group, each data point represents one or two glomerular samples
derived from the pooled renal cortices of 8 to 12 animals. Open circles
denote t5-3H1-orotate infusion in controls: closed circles, [5-3H]-orotate
infusion in diabetics; open triangles, [2-3H]-adenine infusion in con-
trols; closed triangles, [2-3HJ-adenine infusion in diabetics.
term diabetic animals (group 2). The results of experiments in
which insulin and glucagon were infused at different rates were
combined to study the relationships between changes in plasma
IRI, IRG, and glucose concentrations and orotate incorporation
into RNA. Experiment I in Table I shows that when plasma IRI
was restored to control values with the infusion of 3.8 mU of
insulin/kg/mm, hyperglycemia and hyperglucagonemia were
fully corrected. In these animals, both incorporation of orotate
into RNA and RNA specific radioactivity decreased. When
glucagon was added to this insulin infusion at a rate of 3.0 ng/kg/
mm, hyperglucagonemia similar in degree to that seen in
nontreated diabetics was induced although plasma IRI and
glucose concentrations were maintained at values similar to
controls. Under these conditions, RNA incorporation and RNA
specific radioactivity increased substantially (Table I). In the
same experiment, further increases in plasma IRG concentra-
tions produced by infusing glucagon at 6.0 ng/kg/min or by
decreasing the rate of the insulin infusion resulted in still greater
incorporation of radioactivity into RNA, although these infu-
sions with less insulin or more glucagon did increase plasma
glucose concentrations (Table 1).
In a confirmatory experiment, similar results were obtained
although the degree of alteration in plasma hormonal concentra-
tion in these diabetic animals was somewhat different from that
in the previous group (experiment 2, Table 1). The infusion of a
small amount of insulin (1.73 mU/kg/mm) caused an appreciable
decrease in plasma IRG concentration, whereas hyperglycemia
was unchanged and hypoinsulinemia was still present. This
infusion decreased the incorporation of orotate into RNA and
consequent RNA specific radioactivity as compared with non-
treated diabetic animals, Further, addition of glucagon to this
insulin infusion resulted in hyperglucagonemia and reversal of
the effects of insulin on RNA incorporation without change in
plasma IRI or decrease in glucose concentrations (experiment
2, Table 1). As a consequence of the greater incorporation into
RNA, the RNA specific radioactivity in the glomeruli of these
animals treated with insulin plus glucagon increased 39% as
compared with animals receiving insulin only (experiment 2,
Table 1).
When RNA incorporation was correlated with plasma con-
centrations of glucose, IRI, and IRG in these experiments, a
I I
Control 0 2.6 5.2 6.95
Rate of insulin infusion, mU/kg/rn/n
Fig. 3. Incorporation of radiolabeled orotate and adenine into free
nucleotides in the glomeruli of 48-hour diabetic animals: Effect of
insulin infusion. Symbols are the same as in Fig. 2.
significant correlation (P < 0.1) was found with IRG values.
This correlation was positive and linear (significance of linearity
P < .01) (Fig. 4). Multiple regression analysis of the data
revealed that only IRG concentration was significantly related
to RNA incorporation (P = 0.475, 0.566, 0.036 for glucose, IRI,
and IRG, respectively).
Relative effects of glucose, insulin, and glucagon on the
incorporation of labeled orotate into RNA, total nucleotides,
and UTP in the whole renal cortex of short-term diabetic
animals. Forty-eight hours after the induction of diabetes, the
renal cortical content of UTP and RNA were increased as
compared with controls (Table 2).
Because the incorporation of labeled orotate into cortical
UTP and RNA increases linearly during a 150-mm infusion in
control and diabetic animals [8], comparisons of quantities
incorporated can be made at any interval during this infusion.
At the end of a 120-mm infusion, the incorporation into total
nucleotides, UTP, and RNA, and RNA specific radioactivity
were increased 30, 36, 40, and 20%, respectively, in the diabetic
renal cortex (Table 2). In addition, the amount of UTP incorpo-
rated into RNA during the labeling period was increased also
(control 311 6 [N = 9], diabetic 362 [N 8] nmo!es/mg DNA!
hour; P < 0.005).
The 38-hour infusion of a small amount of insulin in diabetic
animals which did not alter the degree of hyperglycemia (ex-
periment 2, Table 1), resulted in a small decrease in UTP
content (10%, P = 0.065) and lesser incorporation of labeled
orotate into total nucleotides, UTP, and RNA (Table 2). As a
consequence of this change in incorporation, UTP and RNA
specific radioactivities were IS and 24% lower, respectively,
than in noritreated diabetics (148 6 [N = 9] vs. 175 5 [N =
8] x 102 dpm!nmoles UTP; P <0.001) (Table 2). The decrease
in RNA labeling was not accompanied by a significant decrease
in the amount of UTP incorporated into RNA (343 7 [N = 9]
nmoles/mg DNA/hour). The addition of glucagon to the insulin
infusion in amounts insufficient to alter plasma concentrations
of glucose or insulin (experiment 2, Table 1) resulted in small
increases in the incorporation of orotate into total nucleotides
(P = 0.061) and (JTP (P = 0.069) and a significantly greater
incorporation into RNA (Table 2). The consequent RNA specif-
ic radioactivity was 11% greater. But, this increase was not
associated with greater incorporation of UTP into RNA (337
5 [N 9] nmoles!mg DNA/hour). In animals receiving gluca-
gon, there were no significant changes in UTP content (Table
2).
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Table 1. Effect of insulin and glucagon on the incorporation of radiolabeled orotate into glomerular RNA in 48-hour diabetic animals
Values are mean SEM
Values represent the mean of two glomerular samples obtained from one pool of renal cortices.
Values in parentheses are number of animals.
Incorporation of labeled orotate into glomerular RIVA in
ion g-term diabetic animals: Effect of insulin (group 3). Seven
months after the induction of the disease, diabetic animals
showed inadequate growth. All had bilateral cataracts. Micro-
scopic examination showed mild or moderate mesangial thick-
ening in all diabetic animals and arteriolar sclerosis in one-
fourth. Glomerular nodular sclerosis was not observed. No
abnormalities were found in the kidneys of age-matched con-
trols.
Functional effects of the renal disease in these diabetic
______________________________
animals were suggested by a twofold increase in plasma urea
concentration (Table 3). The urea concentration was not rnodi-
fled by the 24-hour infusion of insulin, which induced a moder-
ate increase in body weight (diabetic, 150 5 [N — 81; diabetic
+ insulin, 170 8 [N — 7] g, P = 0.057) probably as a result of
sodium and water retention [271.
In the diabetic animals, plasma glucose and IRG concentra-
tions were increased 286% and 89%, respectively, and there
was a 78% decrease in plasma IRI as compared with their
corresponding controls (Table 3). In these animals, the incorpo-
ration of orotate into free nucleotides, RNA. and the resulting
RNA specific radioactivity were markedly reduced compared
with control values (free nucleotides in diabetic, 0.63%; in
control, 1.72% infused dpm/mg DNA) (Table 3). But, at the end
of a 24-hour infusion of insulin, the incorporation of orotate into
free nucleotides and RNA decreased to 86% and 59%, respec-
tively, of that in nontreated diabetic animals (free nucleotides in
treated diabetics, 0.55% infused dpm/mg DNA) (Table 3). The
effects of insulin replacement on RNA incorporation were
demonstrated even when hyperglycemia was unaltered and
hypoinsulinemia still evident (Table 3). But the quantity of
insulin given was sufficient to reverse the marked increase in
plasma IRG concentrations present in these long-term diabetic
animals.
Glomerular RNA content in short- and long-term diabetic
animals. The glomerular content of RNA was not altered
significantly by the infusion of sodium chloride solution in
either normal control or diabetic animals. Thus, for statistical
analysis, RNA/DNA values from noninfused animals were
pooled with values obtained in controls and in infused diabetic
animals not receiving insulin in groups 1 and 2 (Table 4).
Insulin Glucagon Glucose IRI IRG
mU//..g/min ng/kg/min mg/mi pU/mI pg/mi
Treatment Plasma concentration RNA incorporationh
t dpm inji,sed/ Specific activity
ing DNA dp,n/g RNA
Experiment 1'
Control (10) — — 1.70 0.03 187 + 7 221 22 0.120 326
Diabetic (9) — — 4.50 0.14 55 4 492 61 0.276 483
Diabetic (8) 3.8 — 1.20 0.04 198 18 223 41 0.181 355
Diabetic (9) 3.8 3.0 1.16 0.12 228 + 26 364 76 0.226 572
Diabetic (9) 3.8 6.0 2.91 0.53 146 15 409 107 0.308 584
Diabetic (9) 1.73 3.0 4.76 0.16 66 4 743 59 0.399 931
Experiment 2
Diabetic (8) — — 4.30 0.10 27 4 280 33 0.196 365
Diabetic (9) 1.73 — 4.59 0.04 5! 5 166 12 0.172 28!
Diabetic (JO) 1.73 3.0 4.30 0.10 57 3 290 36 0.277 393
y = 117— 873x
r 0.480
4.0
8 —
oo 2.0 —
.2
.
y = 182— 291x
r 0.322
y = —96 + 1884x
= 0.895
S/
600
200 •,'•
— .
0.1 0.3
Incorporated into RNA, % dpm/mg DNA
Fig. 4. Relationship between incorporation of radioiabeied orotate into
glonierular RNA and the plasma concentrations of glucose, i,nmunore-
active insulin and immunoreactive glucagon in 48—hour diabetic ani—
ma/s. Values plotted correspond to those in experiments I and 2 of
Table I.
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Table 2. Effect of insulin and glucagon on the content of UTP and RNA, and on the incorporation of radiolabeled orotate into total nucleotides,
UTP and RNA in the renal cortex of 48-hour diabetic animals
Cortical incorporationb
Treatment
Insulin Glucagon
mU/kg/mm ng/kg/min
Cortical contentb Total
nucleotides UTP RNA
-______ -
% dpm infused/mg DNA
RNA
specific activity5
dpm/p4
UTP
nmoles/mg DNA
RNA
mg/mg DNA
Control (10) — — 438 8 1.42 0.03 17.6 0.5 4.38 0.13 3.11 0.08 2635 114
Diabetic (8) — — 497 18' 1.87 0.03" 22.9 0.9" 5.97 0.24' 4.36 0.20" 3157 46"
Diabetic (9) 1.73 — 452 14 1.82 0.02 19.4 l.ld 5.03 0.24d 3.82 0.16d 2547 96d
Diabetic (10) 1.73 3.0 490 25r 1.76 0.03" 21,8 0.7' 5.96 0.41" 4.34 0.l1"- 2842 65
"The samples studied originated from the same animals as in experiment 2 of Table I. Control values correspond to animals in experiment I of
Table I. Values in parenthesis are number of animals.
b Values are mean SEM.
"Significant differences are, diabetic vs. control, I' = 0.01 or less.
Significant differences are, diabetic vs. insulin-treated diabetic, P — 0.05 or less.
Significant differences are, insulin-treated diabetic vs. insulin and glucagon-treated diabetic, P = 0.025 or less.
Urea
mg/mi
0.321 0.032
0.688 0.049
0.617 0.066
In isolated normal glomeruli, the content of RNA per unit
DNA was only a fraction of the content in whole renal cortex
(Tables 2 and 4). RNA content was slightly increased in
glomeruli 48 hours after the induction of diabetes (Table 4). This
12% increase was about the same as that observed in random
samples of whole renal cortex of the same diabetic and control
animals in which RNA/DNA was 1.93 0.02 [N = 13] and 1.77
0.02 [N 101 mg RNA/mg DNA, respectively, or 9% greater
than control values (P < 0.001). But, in other experiments,
renal cortical RNA/DNA increased up to 32% (Table 2). Signifi-
cant differences in glomerular RNA content were not evident
when results were expressed as per unit of protein (Table 4).
RNA/DNA did not change in 48-hour diabetics after the infu-
sion of insulin at any of the rates tested.
Glomerular RNA content in long-term diabetic animals was
appreciably greater than in age-matched controls, an increase
partially reversed by insulin administration (Table 4). But,
statistical analysis of the differences was not possible due to the
small number of diabetic animals that survived long periods of
the disease and subsequent surgery required for the insertion of
chronic intravenous cannulae.
Discussion
This study demonstrates the participation of glomeruli in the
metabolic changes that occur in whole renal cortex shortly after
the induction of diabetes [18]. The observations reported here
were made 48 hours after the injection of streptozotocin, but
this drug does not induce hyperglycemia and hypoinsulinemia
for several hours after its administration [8, 17]. Hence, the
metabolic changes probably developed 24 to 36 hours after
diabetes was established.
The degree of labeling of RNA with exogenous precursors is
the end result of several variables [28]. These include cellular
transport, synthesis rate of nucleotide precursors, dilution in
endogenous pools, synthesis and breakdown rates of RNA, and
possible changes in nucleotide pool compartmentation. Red
cells, hepatocytes and renal cortical cells are highly permeable
to orotate, hence its rate of incorporation into nucleotides
appears limited only by the rate of its conversion to orotidine 5'-
phosphate and uridine 5'-phosphate [28—31]. Because orotate
and orotidine 5'-phosphate are rapidly metabolized and do not
accumulate intracellularly [32], exogenous orotate taken up by
the cell will be diluted only in the pool of uracil phosphates.
The measurement of the endogenous pool of uracil phos-
phates in isolated glomeruli is probably inaccurate because
during the process of glomerular separation the tissue is subject
to ischemia and cooling. These two factors caused marked
alterations in the renal contents of nucleotides [33, 34]. The lack
of information on the endogenous precursor pools in vivo
prevents an understanding of the reasons for increased incorpo-
ration of labeled orotate into glomerular RNA. But, the change
in labeling of total nucleotides and RNA appears to be limited to
pyrimidine derivatives because no alteration was found in the
incorporation of adenine under identical conditions.
The absence of greater RNA incorporation of adenine when
glomerular RNA content is increased suggests that its degree of
Table 3. Effects of 24-hour insulin infusion on the incorporation of radiolabeled orotate into glomerular RNA in long-term diabetic rats
Plasma concentration" RNA incorporationh
Insulin treatment Glucose IRI IRG Specific activity
mU/kg/mm mg/mi ILU/mi pg/mi dpm infused/mg DNA dpm/i.g RNA
Control (7)" — 1.62 0.14 209 33 334 9 0.607 1253
Diabetic (8) — 4.64 t).18 47 4 631 45 0.325 768
Diabetic (6) 6.8 4.36 0.64 63 7 378 27 0.193 401
a Values are mean SEM.
Values represent the mean of two glomerular samples obtained from one pool of renal cortices.
Values in parenthesis are number of animals.
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incorporation does not correlate with the rate of RNA synthe-
sis. In the whole growing renal cortex, calculated ATP incorpc-
ration into RNA after labeling with 3H-adenine is increased
(unpublished observations). Possibly, increased glomerular
RNA synthesis may not he the primary mechanism for RNA
accretion; decreased breakdown of ribosomal RNA could have
the same result as that shown in the growing mouse kidney [35].
In the whole renal cortex of 48-hour diabetic animals, the
excessive incorporation of labeled orotate into RNA is probably
a consequence of: (a) enhanced synthesis of uracil nucleotides,
as suggested by the increased incorporation of orotate into UTP
and expansion of the UTP pooi, and (b) increased synthesis cf
RNA, as suggested by the greater incorporation of UTP into
RNA (if a proportional expansion of all compartmented UTP
pools is assumed) [8, 18]. In contrast, the decreased labeling
induced by the infusion of small amounts of insulin is probably
the result only of a change in the incorporation of labeled
orotate into uracil nucleotides because the incorporation of
UTP into RNA remained unchanged. These observations were
made under conditions of steady-state plasma hormone concen-
tration because the administration of labeled orotate was car-
ried out after 36 to 38 hours of continuous insulin infusion,
which is well past the 1- to 3-hour period required to achieve
constant plasma concentrations [36, 37].
The increased incorporation of orotate into glomerular RNA
in diabetic animals was partially or totally prevented by the 38-
hour infusion of insulin. The change induced by a small amount
of insulin was similar in whole renal cortex and glomeruli (14%)
when results from both tissues were compared in the same
animals (experiment 2, Tables I and 2).
In this study, increased RNA content per glomerular cell was
found in early and long-term diabetic animals. But, the latter
observation was made in only a few animals that survived 7
months of untreated diabetes. Glomerular RNA was not in-
creased in diabetics when expressed according to the protein
content of the sample, probaby because in diabetic, as in
compensatory renal growth, there is a concurrent increase in
the cellular contents of both RNA and protein [16, 38]. The
exaggerated incorporation of orotate was directly related to the
diabetic state rather than to nephrotoxic effects occurring after
the administration of streptozotocin [39, 40] because optimal
insulin replacement reversed the abnormality.
The similarities between the renal metabolic alterations of
diabetes and those of compensatory growth [9, 10, 41] suggest
that the changes found in diabetic glomeruli represent early
events of glomerular hypertrophy. These would precede func-
tional alterations because GFR is not increased until day 4 after
the injection of streptozotocin in rats [6].
Orotate incorporation into glomerular RNA was less in 7-
month diabetic animals than it was in age-matched controls,
probably as a consequence of the degree of renal disease
present in these long-term diabetic animals. The lower rate of
incorporation was still excessive for these diseased glomeruli,
as demonstrated by the further decrease induced by insulin
replacement. Thus, the glomerular metabolic changes of early
diabetes probably persist for long periods of the disease al-
though they may be difficult to demonstrate because of concur-
rent renal damage.
Hyperglucagonemia, absolute or relative to plasma glucose
concentrations, is present in most forms of experimental and
2-Month old ratsh
Control (14) 0.651 0.028 10.6 0.4
2-Day diabetic (14) 0.73 1 0.024
P < 0.05
11.6 0.7
P > 0.05
9-Month old rats'
Control (2) 0.829 7.69
7-Month diabetic (1) 1.097 9.37
Insulin treated (1) 0.902 8.74
spontaneous diabetes mellitus with insulin deficiency [42—44],
but the biochemical effects of glucagon on the diabetic kidney
have not been determined. This study demonstrates a direct
correlation of the glomerular metabolic changes at the onset of
diabetes with elevated plasma glucagon concentrations of a
magnitude similar to those found in diabetic animals. This
correlation was independent of the existing plasma concentra-
tions of insulin and glucose.
Some of the cortical metabolic changes of early diabetes
seemed to be associated also with hyperglucagonemia. In whole
renal cortex, glucagon probably increased the labeling of RNA
by enhancing the incorporation of orotate into the nucleotide
precursor pool with a consequent change in its specific radioac-
tivity. The effects of hyperglucagonemia were more prominent
in glomeruli than in whole renal cortex. Although RNA incorpo-
ration in the glomeruli was increased 61% after a 38-hour
infusion of insulin to which glucagon was added, the corre-
sponding change in the renal cortex of the same animals was
13% (experiment 2, Tables I and 2).
Absolute hyperglucagonemia in short-term diabetic animals
was corrected by the continuous infusion of insulin at rates
insufficient to restore plasma glucose and insulin concentrations
to control values. Although insulin is a potent suppressor of
glucagon release by the a2-cell [45, 46], complete reversal of
hypergiucagonemia in human diabetes is difficult to achieve
with conventional insulin therapy [47]. It is likely that a
constant supply of insulin is more effective in suppressing
glucagon secretion than the same total dose given intermittently
[48].
In long-term diabetic animals, in which hyperglucagoriemia
was most marked, 24-hour infusion of insulin at rates insuffi-
cient to correct hyperglycemia decreased plasma glucagon to
control values. This was accompanied by a decrease in RNA
and total free nucleotide incorporation of precursor. The
changes in incorporation after reversal of absolute hypergluca-
gonemia suggest that, as in early diabetes, glucagon excess may
be a factor in the glomerular metabolic alterations of long-term
diabetes.
Short-term infusion of pharmacological doses of glucagon
(200 to 600 ng/kg/min) in experimental animals results in in-
creased GFR, RPF, and filtration fraction [49—511. In normal
man, a 2-hour infusion of glucagon at a rate of 10 ng/kg/min
causes a steady fourfold increase in plasma glucagon concentra-
Table 4. Glomerular RNA content in diabetic animals
RNA content
ig/ig DNA p.g/ing protein
a Values are mean SEM.
' Values in parenthesis represent the number of glomerular pools
studied. Two samples were analyzed from each pool and their means
used for statistical analysis.
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tion within 30 mm and a 9% increase in GFR and filtration
fraction [52]. The quantities of glucagon infused in this study
were lower than those required to induce these functional
changes. But, in well-controlled juvenile diabetics a short-term
infusion (20 to 60 mm) of low doses of glucagon (4 to 5 ng/kgl
mm) results in twofold increase in its plasma concentration and
a 6% greater GFR [53]. It is not known if these acute functional
changes persist after prolonged infusions, In the present stud-
ies, a linear correlation was obtained between orotate incorpo-
ration into glomerular RNA and plasma concentrations of
glucagon from 75 to 336% of control values, which are well
within the physiologic and diabetic range. Thus, the glomerular
alterations were probably due to a direct metabolic effect of
glucagon, but the biochemical consequences of preceding acute
functional changes induced during the infusion of this hormone
are unknown.
Increased plasma concentration of growth hormone has been
hypothesized to be a determinant of increased GFR and renal
mass in diabetes and as a causative factor in diabetic glomeru-
losclerosis [54, 55]. But, the concentration of plasma growth
hormone is decreased in rats with streptozotocin-induced dia-
betes [8], and there is no correlation between concentrations of
this hormone and GFR in young patients with recent and short-
term diabetes [56].
The synthesis of uracil nucleotides from orotate can be
enhanced by glucagon through increased formation of 5-phos-
phoribosyl 1-pyrophosphate (PRPP). The concentration and
bioavailability of PRPP are some of the major determinants of
the regulation of pyrimidine synthesis de novo 157, 58]. Gluca-
gon stimulates PRPP synthesis in liver cells in vivo and in vitro
[59, 60]. In addition, the bioavailability of PRPP increases in the
rat renal cortex shortly after the induction of diabetes [61].
The increased synthesis of uracil nucleotides and subsequent
expansion of their endogenous pools may be factors in the
development of diabetic glomerular disease in addition to their
participation in compensatory and diabetic renal growth.
Chronic orotate administration enhances the formation of renal
cortical uridine triphosphate and induces thickening of the
glomerular basement membrane in normal rats [62].
It is proposed that hyperglucagonemia, independently of
plasma insulin and glucose concentrations, may be a factor in
the development of glomerular growth and basement membrane
thickening in diabetes. These effects of glucagon could be
mediated by alterations in uracil nucleotide metabolism.
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